Loading...
BEAM logo

Beam Therapeutics Community

NasdaqGS:BEAM Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 38 Fair Values set on narratives written by author

Community Investing Ideas

BEAM logo
Beam Therapeutics

Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases

Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.

View narrative
0users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
US$45.92
40.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
13.91% p.a.
Profit Margin
16.06%
Future PE
469.09x
Share price in 2028
US$55.74